Roger Echols is Principal of Infectious Diseases at Drug Development Consulting, LLC, a consulting firm established in 2008 focused on the development of anti-microbial therapies including drugs, biologics and devices.
Roger is a physician trained in infectious diseases who has extensive experience in the development of anti-bacterial, anti-viral and antifungal drugs both in the USA and internationally. His career in the pharmaceutical industry started in 1989 as Medical Director at Bayer leading the USA development of ciprofloxacin. Before this, he was Head of the Division of Infectious Diseases at Albany Medical College and an attending physician at Albany Medical Center. From 1996 to 1997, he was Medical Director at Immunex Corporation (GmCSF) and was Vice President of Infectious Disease Clinical Research and Development at Bristol Myers Squibb from 1997-2004. Roger has also served as the Chief Medical Officer of Replidyne, Inc from 2005-2008 helping to take the company public in 2007.
As a consultant, he has explored novel antimicrobial projects including biologics and devices, as well as more traditional antibiotics that address targets defined as urgent by the U.S. centers for disease control and prevention (CDC) and the biodefense community. Roger has had numerous opportunities to interact with the FDA and EMA, including public workshops and advisory committee presentations. He is a Fellow in the Infectious Disease Society of America and has more than 100 peer-review publications, most involving anti-infective research and clinical development.
Roger received his bachelor’s degree from Yale University, USA and his medical degree from Tufts University School of Medicine, USA and completed his Infectious Diseases training at the University of New Mexico also in the USA.